| Original language | English |
|---|---|
| Article number | 357 |
| Journal | BMC Infectious Diseases |
| Volume | 18 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2018 |
Keywords
- Cholesterol
- Dyslipidemia
- Framingham risk score
- Integrase inhibitors
- Rilpivirine
- cholesterol
- dolutegravir
- efavirenz
- elvitegravir
- high density lipoprotein cholesterol
- lipid
- low density lipoprotein cholesterol
- rilpivirine
- ritonavir
- triacylglycerol
- virus RNA
- adult
- antiretroviral therapy
- Article
- cholesterol blood level
- cohort analysis
- controlled study
- drug substitution
- drug withdrawal
- dyslipidemia
- female
- follow up
- human
- Human immunodeficiency virus infection
- lipid analysis
- major clinical study
- male
- observational study
- prospective study
Cite this
Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: Results from a large observational cohort study (SCOLTA). / Taramasso, L.; Tatarelli, P.; Ricci, E.; Madeddu, G.; Menzaghi, B.; Squillace, N.; De Socio, G.V.; Martinelli, C.; Gulminetti, R.; Maggi, P.; Orofino, G.; Vichi, F.; Di Biagio, A.; Bonfanti, P.; Bellacosa, C.; Calza, L.; Abeli, C.; Celesia, B.M.; Grosso, C.; Stagno, A.; Mazzotta, F.; Penco, G.; Cassola, G.; Nicolini, L.A.; Dentone, C.; Molteni, C.; Palvarini, L.; Scalzini, A.; Carenzi, L.; Rizzardini, G.; Valsecchi, L.; Cordier, L.; Rusconi, S.; Colombo, V.; Galli, M.; Franzetti, M.; Sgrelli, A.; Mazzotta, E.; Parruti, G.; Bagella, P.; Mura, M.S.; Libertone, R.; Antinori, A.; Di Giambenedetto, S.; Guastavigna, M.; Caramello, P.
In: BMC Infectious Diseases, Vol. 18, No. 1, 357, 2018.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: Results from a large observational cohort study (SCOLTA)
AU - Taramasso, L.
AU - Tatarelli, P.
AU - Ricci, E.
AU - Madeddu, G.
AU - Menzaghi, B.
AU - Squillace, N.
AU - De Socio, G.V.
AU - Martinelli, C.
AU - Gulminetti, R.
AU - Maggi, P.
AU - Orofino, G.
AU - Vichi, F.
AU - Di Biagio, A.
AU - Bonfanti, P.
AU - Bellacosa, C.
AU - Calza, L.
AU - Abeli, C.
AU - Celesia, B.M.
AU - Grosso, C.
AU - Stagno, A.
AU - Mazzotta, F.
AU - Penco, G.
AU - Cassola, G.
AU - Nicolini, L.A.
AU - Dentone, C.
AU - Molteni, C.
AU - Palvarini, L.
AU - Scalzini, A.
AU - Carenzi, L.
AU - Rizzardini, G.
AU - Valsecchi, L.
AU - Cordier, L.
AU - Rusconi, S.
AU - Colombo, V.
AU - Galli, M.
AU - Franzetti, M.
AU - Sgrelli, A.
AU - Mazzotta, E.
AU - Parruti, G.
AU - Bagella, P.
AU - Mura, M.S.
AU - Libertone, R.
AU - Antinori, A.
AU - Di Giambenedetto, S.
AU - Guastavigna, M.
AU - Caramello, P.
N1 - Export Date: 18 January 2019 CODEN: BIDMB Correspondence Address: Taramasso, L.; University of Genoa, Department of Health Sciences (DISSAL)Italy; email: taramasso.lucia@gmail.com
PY - 2018
Y1 - 2018
KW - Cholesterol
KW - Dyslipidemia
KW - Framingham risk score
KW - Integrase inhibitors
KW - Rilpivirine
KW - cholesterol
KW - dolutegravir
KW - efavirenz
KW - elvitegravir
KW - high density lipoprotein cholesterol
KW - lipid
KW - low density lipoprotein cholesterol
KW - rilpivirine
KW - ritonavir
KW - triacylglycerol
KW - virus RNA
KW - adult
KW - antiretroviral therapy
KW - Article
KW - cholesterol blood level
KW - cohort analysis
KW - controlled study
KW - drug substitution
KW - drug withdrawal
KW - dyslipidemia
KW - female
KW - follow up
KW - human
KW - Human immunodeficiency virus infection
KW - lipid analysis
KW - major clinical study
KW - male
KW - observational study
KW - prospective study
U2 - 10.1186/s12879-018-3268-5
DO - 10.1186/s12879-018-3268-5
M3 - Article
VL - 18
JO - BMC Infectious Diseases
JF - BMC Infectious Diseases
SN - 1471-2334
IS - 1
M1 - 357
ER -